Scientist are usually not business people , obviously many bought the 2.50 /listing acquisition story , turnkey ops to generate revenue and the legacy portfolio of the company. The past two years include many "missed" PR's and I think big money will support and invest in potential future plans/management.........so far still the missing link. Based on performance and due diligence it could be a problem to line up solid support under current conditions...........if listed (both companies) and trading between 10-20 I will be happy to admit my opinion was not correct........and these numbers are low considering "potential" billions .............